ArticleFrontiers in oncology2026
PD-1 inhibitor-induced systemic sclerosis with early interstitial lung disease and autoimmune thyroiditis in advanced gastric cancer: a case report and literature review.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICIs) have revolutionized anti-tumor therapy, yet their use is increasingly complicated by immune-related adverse events (irAEs). We present a rare case in which sequential administration of two PD-1 inhibitors (ICIs), Camrelizumab and Sintilimab, in combination with conventional chemotherapy led to ICI-related systemic sclerosis (ICI-SSc) with early-stage interstitial lung disease (ILD) and autoimmune thyroiditis (AIT). The clinical presentation also suggested a possible scleroderma overlap syndrome. The underlying pathology is likely linked to widespread immune activation following PD-1 pathway blockade. Early identification of ICI-SSc is crucial. Once the diagnosis is confirmed, the suspected drug should be discontinued immediately, and a personalized treatment plan should be initiated, ideally with consideration of the safety profile of steroid-based regimens. Furthermore, our findings raise important considerations regarding pharmacovigilance in the context of sequential ICIs use.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.